Liquid Biopsy Evaluation and Repository Development at Princess Margaret
- Sponsor
- University Health Network, Toronto
- Study ID
- NCT03702309
- Status
- Recruiting
Conditions
- BRCA1 Mutation
- BRCA2 Mutation
- Breast Cancer
- Cancer
- Colon Cancer
- Cowden Syndrome
- Head and Neck Cancer
- Kidney Cancer
- Leukemia
- Lung Cancer
- Lymphoma
- Lynch Syndrome
- Melanoma
- Meningioma
- Mutation
- Myeloma
- Ovarian Cancer
- Uterine Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
Key Dates
- First listed
- Oct 11, 2018
- Start date
- Aug 3, 2017
- Status verified
- Nov 2025
- Primary completion
- Jul 6, 2026
- Completion
- Jul 6, 2026
Study Design
- Enrollment
- 2,500 participants (estimated)
Arms
- Arm: LIBERATEPatients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
Primary Outcome Measure
Collection and annotation of biospecimens [ Time Frame: Through study completion, up to 5 years ]
Central Contacts
- Celeste Yu, MSc416-946-4501
Find similar trials
Related Studies
- Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Evaluation of Late Effects and Natural History of Disease in Patients Treated With RadiotherapyRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland